Development of an individual Anti-FVIII Inhibitors ELISA to improve Haemophiliacs therapeutic follow up Peyrafitte M.1, Vissac A.M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, France. 2HYPHEN BioMed, Neuville sur Oise, France
The multiple faces of tissue factor measured with laboratory assays Laroche M.1, Peyrafitte M.1, Vissac A.M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, 2HYPHEN BioMed, Neuville sur Oise, France
Microparticles exposing Tissue Factor in human plasma Laroche M.1, Vissac A.M.1, Peyrafitte M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, France 2HYPHEN BioMed, Neuville sur Oise, France
NEQAS Blood Coagulation Annual Scientific Meeting September 2012 -20 September 2012
We had our usual space at this annual meeting and managed to sit in on some excellent presentations.
Update on Potential New Anticoagulants - www.pmlive.com -08 August 2012
Modern anticoagulants threaten status quo. Could the shift towards first-in-class novel oral treatments, which are expected to prove beneficial for prevention of stroke caused by AF, render warfarin obselete?
Quadratech are liaising with our couriers ‘Wey Group International’ to minimise the disruption caused by the London 2012 Olympics.
EXHIBITIONS AND MEETINGS FOR 2012 -19 April 2012
Quadratech will be exhibiting at or attending the following meetings in 2012
EXHIBITIONS AND MEETINGS FOR 2011 -15 December 2011
2011 is a landmark year for Quadratech as it is our 20th Birthday. The company was founded in 1991 and has continued to grow and thrive over the intervening years, to the company you know today.
MICROPARTICLES MEETING -11 October 2011
In September 2010 amongst the dreaming spires of Oxford's Magdalen College the topic of 'Micro and Nanovesicles in Health and Disease' was explored.
NEQAS ANNUAL SCIENTIFIC MEETING -11 October 2011
The NEQAS Blood Coagulation Annual Scientific Meeting, held in Sheffield on 8th and 9th September 2010, was as usual very well attended and received.